Dexmedetomidine for Postoperative Analgesia After Bariatric Surgery
Phase 2
Completed
- Conditions
- ObesitySleep ApneaHypertensionDiabetes
- Interventions
- Registration Number
- NCT02213159
- Lead Sponsor
- American University of Beirut Medical Center
- Brief Summary
The purpose of this study is to determine if Dexmedetomidine given at the end of surgery will reduce postoperative morphine consumption and improve postoperative quality of recovery as compared to morphine in patients undergoing laparoscopic bariatric surgery.
- Detailed Description
effect of Dexmedetomidine bolus on postoperative morphine requirements
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
- Body Mass Index > 40 kg/m2 or BMI > 35 kg/m2 with comorbid conditions such as hypertension, diabetes or sleep apnea
- American Society of Anesthesiologists class I or II
- Undergoing laparoscopic sleeve gastrectomy bariatric surgery
Exclusion Criteria
- Allergy to morphine or its derivatives
- Allergy to α-2 adrenergic agonists
- weight over 180 kg
- history of uncontrolled hypertension
- heart block greater than first degree
- prolonged QT interval
- clinically significant neurologic, cardiovascular, renal, hepatic, or gastrointestinal diseases
- received an opioid analgesic medication within a 24 h period prior to surgery
- history of alcohol, drug abuse or chronic opioid intake
- history of psychiatric disorder
- pregnant or breastfeeding.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Dexmedetomidine Dexmedetomidine prior to anticipated end of surgery bolus of 1 microgram/kg Dexmedetomidine intravenously over 10 minutes followed by 0.5 micrograms/kilogram/hour intravenous infusion until removal of laparoscopes Morphine Morphine prior to anticipated completion of surgery morphine 0.08 mg/kilogram intravenous bolus over 10 minutes followed by a saline infusion until removal of the laparoscopes
- Primary Outcome Measures
Name Time Method Total dose of morphine consumed in Post Anesthesia Care Unit (PACU) At discharge from the PACU
- Secondary Outcome Measures
Name Time Method Numeric Rating Scale (NRS) for Pain in the PACU and at 24 hours NRS for nausea in the PACU incidence of pruritus in the PACU incidence of respiratory complications in the PACU time to discharge readiness in PACU in the PACU total morphine consumption at 24 hours at 24 hours Quality of Recovery (QoR-40) score at 24 hours at 24 hours overall satisfaction at one month one month after surgery Time to first morphine requirement in PACU in the PACU incidence of vomiting or retching in the PACU
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which Dexmedetomidine modulates postoperative pain pathways in bariatric surgery patients?
How does Dexmedetomidine compare to Morphine in reducing postoperative opioid requirements and improving recovery in laparoscopic bariatric surgery?
Are there specific biomarkers that can predict patient response to Dexmedetomidine in postoperative analgesia for obesity-related comorbidities?
What are the potential adverse events associated with intraoperative Dexmedetomidine use in patients with hypertension and diabetes undergoing bariatric surgery?
What combination analgesic strategies involving Dexmedetomidine are being explored for postoperative pain management in morbidly obese patients with sleep apnea?
Trial Locations
- Locations (1)
American University of Beirut Medical Center
🇱🇧Beirut, Lebanon
American University of Beirut Medical Center🇱🇧Beirut, Lebanon